<DOC>
	<DOCNO>NCT01627132</DOCNO>
	<brief_summary>The purpose study ass whether dasatinib discontinue without occurrence molecular relapse patient chronic myeloid leukemia chronic phase complete molecular remission ( CMR ) dasatinib .</brief_summary>
	<brief_title>Discontinuation Dasatinib Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission Two Years ; Dasatinib Stop Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Chronic Myeloid Leukemia Chronic Phase . Patients BCRABLnegative check . 15 year old . ECOG performance status ( PS ) score 02 . Adequate organ function ( hepatic , renal lung ) . Signed write informed consent . A case double cancer activity . Women pregnant breastfeeding . Patients complication history severe . Patients mutation T315I、F317L、V299L . Patients additional chromosome abnormality . The case Pleural effusion poor control . Patients history hematopoietic stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>